The Value of Atorvastatin Over the Product Life Cycle in the United States

Heart Disease and Stroke Statistics—2011 Update

Véronique L. Roger, Alan S. Go, Donald M. Lloyd‐Jones et al. · Circulation · 2010 · 6.2K citations · Full text

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

Christopher P. Cannon, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine · 2004 · 4.9K citations · Full text

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Peter Sever, Björn Dahlöf, Neil R Poulter et al. · The Lancet · 2003 · 3.8K citations

Thrombosis, Hypertension, Cardiovascular Disease +12

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington et al. · The Lancet · 2004 · 3.8K citations

Metabolic Syndrome, Primary Prevention, Diabetes Management +8

Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease

John C. LaRosa, Scott M. Grundy, David D. Waters et al. · New England Journal of Medicine · 2005 · 3.5K citations · Full text